News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,406 Results
Type
Article (25439)
Company Profile (110)
Press Release (236857)
Section
Business (66824)
Career Advice (524)
Deals (11203)
Drug Delivery (42)
Drug Development (48979)
Employer Resources (41)
FDA (6398)
Job Trends (5669)
News (130311)
Policy (10515)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (4)
2024 Bio NC Digital (5)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (4)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (3)
2026 Biotech Bay Standard (1)
2026 Pharm Country Premier (1)
Academia (1536)
Academic (1)
Accelerated approval (4)
Adcomms (16)
Allergies (35)
Alliances (20339)
ALS (71)
Alzheimer's disease (682)
Antibody-drug conjugate (ADC) (110)
Approvals (6417)
Artificial intelligence (101)
Autoimmune disease (14)
Automation (8)
Bankruptcy (97)
Best Places to Work (5137)
BIOSECURE Act (5)
Biosimilars (56)
Biotechnology (95)
Bladder cancer (41)
Brain cancer (20)
Breast cancer (179)
Cancer (1681)
Cardiovascular disease (60)
Career advice (447)
Career pathing (7)
CAR-T (153)
Cell therapy (441)
Cervical cancer (15)
Clinical research (38356)
Collaboration (447)
Compensation (127)
Complete response letters (14)
COVID-19 (1343)
CRISPR (37)
C-suite (98)
Cystic fibrosis (73)
Data (1307)
Denatured (9)
Depression (13)
Diabetes (97)
Diagnostics (2336)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (10)
Drug discovery (62)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (55)
Earnings (24914)
Editorial (12)
Employer branding (7)
Employer resources (37)
Events (38612)
Executive appointments (271)
FDA (7002)
Featured Employer (20)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (341)
Gene editing (94)
Generative AI (12)
Gene therapy (251)
GLP-1 (257)
Government (1461)
Grass and pollen (2)
Guidances (26)
Healthcare (7212)
Huntington's disease (10)
IgA nephropathy (14)
Immunology and inflammation (73)
Indications (20)
Infectious disease (1408)
Inflammatory bowel disease (72)
Inflation Reduction Act (2)
Influenza (24)
Intellectual property (49)
Interviews (113)
IPO (5666)
IRA (6)
Job creations (796)
Job search strategy (370)
Kidney cancer (10)
Labor market (5)
Layoffs (180)
Leadership (3)
Legal (1368)
Liver cancer (58)
Lung cancer (298)
Lymphoma (135)
Machine learning (1)
Management (13)
Manufacturing (131)
MASH (25)
Medical device (2884)
Medtech (2887)
Mergers & acquisitions (5787)
Metabolic disorders (237)
Multiple sclerosis (56)
NASH (5)
Neurodegenerative disease (46)
Neuropsychiatric disorders (7)
Neuroscience (965)
NextGen: Class of 2025 (2263)
Non-profit (1218)
Northern California (1200)
Now hiring (7)
Obesity (106)
Opinion (99)
Ovarian cancer (63)
Pain (22)
Pancreatic cancer (49)
Parkinson's disease (73)
Partnered (10)
Patents (112)
Patient recruitment (55)
Peanut (18)
People (18288)
Pharmaceutical (17)
Phase I (14049)
Phase II (17521)
Phase III (11482)
Pipeline (642)
Podcasts (37)
Policy (25)
Postmarket research (945)
Preclinical (6541)
Press Release (62)
Prostate cancer (55)
Psychedelics (11)
Radiopharmaceuticals (119)
Rare diseases (264)
Real estate (1665)
Recruiting (16)
Regulatory (8743)
Reports (18)
Research institute (1451)
Resumes & cover letters (71)
Rett syndrome (3)
RNA editing (3)
RSV (14)
Schizophrenia (25)
Series A (67)
Series B (36)
Service/supplier (3)
Sickle cell disease (57)
Southern California (1015)
Special edition (5)
Spinal muscular atrophy (115)
Sponsored (19)
Startups (1503)
State (1)
Stomach cancer (12)
Supply chain (16)
Tariffs (1)
The Weekly (27)
United States (10304)
Vaccines (323)
Venture capitalists (17)
Webinars (4)
Weight loss (64)
Women's health (16)
Worklife (5)
Date
Last 7 days (317)
Last 30 days (1266)
Last 365 days (16990)
2025 (4117)
2024 (17854)
2023 (19872)
2022 (25025)
2021 (26136)
2020 (22717)
2019 (17087)
2018 (12984)
2017 (13399)
2016 (12188)
2015 (14506)
2014 (10000)
2013 (8314)
2012 (8430)
2011 (8399)
2010 (7210)
Location
Africa (219)
Alabama (20)
Alaska (4)
Arizona (51)
Arkansas (2)
Asia (17416)
Australia (3382)
California (2677)
Canada (874)
China (294)
Colorado (103)
Connecticut (109)
Delaware (84)
Europe (38254)
Florida (314)
Georgia (74)
Idaho (27)
Illinois (175)
India (8)
Indiana (68)
Iowa (4)
Japan (76)
Kansas (56)
Kentucky (7)
Louisiana (3)
Maine (45)
Maryland (398)
Massachusetts (2224)
Michigan (80)
Minnesota (139)
Missouri (24)
Montana (11)
Nebraska (9)
Nevada (19)
New Hampshire (10)
New Jersey (835)
New Mexico (16)
New York (889)
North Carolina (409)
North Dakota (7)
Northern California (1200)
Ohio (88)
Oklahoma (7)
Oregon (9)
Pennsylvania (610)
Puerto Rico (3)
Rhode Island (11)
South America (345)
South Carolina (1)
South Dakota (1)
Southern California (1015)
Tennessee (16)
Texas (449)
Utah (56)
Virginia (72)
Washington D.C. (10)
Washington State (404)
West Virginia (2)
Wisconsin (12)
262,406 Results for "nature cell".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.
March 31, 2025
·
5 min read
·
BioSpace Insights
Pharm Country
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease.
June 12, 2024
·
5 min read
Mergers & acquisitions
AstraZeneca Makes Potential $1B Cell Therapy Play in EsoBiotec Buy
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.
March 17, 2025
·
2 min read
·
Tristan Manalac
Biotech Bay
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.
June 10, 2024
·
5 min read
Press Releases
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation
Sana Biotechnology, Inc. today highlighted that Nature Biotechnology has published a paper titled “Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain.”
May 21, 2024
·
6 min read
Business
Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.
March 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
YourChoice Therapeutics Announces Nature Publication
March 13, 2025
·
4 min read
Press Releases
Small Cell Lung Cancer Market Size to Reach USD 23.0 Billion by 2035, Impelled by Improved Early Diagnosis & Biomarker Research
Small Cell Lung Cancer Market Outlook 2025-2035:
February 17, 2025
·
9 min read
Policy
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
Replay and The University of Texas MD Anderson Cancer Center, announced that the Food & Drug Administration has issued a ‘safe to proceed’ for the Investigational New Drug application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer cell therapy for relapsed/refractory myeloid malignancies.
April 30, 2024
·
5 min read
Pharm Country
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsCompany Presenting at ASGCT Annual Meeting
Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year’s American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
April 8, 2024
·
5 min read
1 of 26,241
Next